Mutation-directed CAR T cell therapy feasible in recurrent glioblastoma – medwireNews
medwireNews |
Mutation-directed CAR T cell therapy feasible in recurrent glioblastoma
medwireNews medwireNews: Treatment with autologous chimeric antigen receptor (CAR) T cells directed against the epidermal growth factor receptor variant III (EGFRvIII) mutation is feasible and well tolerated in patients with recurrent glioblastoma, indicates a … |
